HC Wainwright Rates Galectin Therapeutics (GALT) buy

HC Wainwright maintains its buy rating for GALT, setting a price target of $11, a 165.69% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 1:02 PM EDT · Updated Jun 26, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Galectin Therapeutics Inc. ($GALT) "buy" with a $11 price target on June 23, 2026.

Since the rating, $GALT is up 48.7% after 1 week, up 10.6% after 1 month and up 16.0% to date (from the $3.12 close on Jun 23, 2026).

GALT Galectin Therapeutics Inc.

$3.62 -10.62% year to date

Daily close · Oct 16, 2026

Key Points

HC Wainwright reiterated its buy rating for GALT on June 23, 2026, with a price target of $11.
HC Wainwright's $11 price target implies 165.69% upside from Galectin Therapeutics Inc.'s ($GALT) current $4.14 share price.
GALT shares traded at $3.50 on Tuesday, reflecting ongoing interest from institutional investors.
Vanguard Capital Management opened a new position in GALT, while Marshall Wace increased its stake by 102.6%.

Get $GALT trade alerts by text

We text you when insiders, Congress or big funds trade $GALT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Galectin Therapeutics Inc. alert may contain errors. Disclosures

On June 23, 2026, HC Wainwright reiterated its buy rating for GALT, setting a price target of $11. The analyst Matthew Keller maintains a positive outlook on the stock, which traded at $3.50 on Tuesday.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +52.69% hypothetical

All-time return +154.20% S&P 500 +27.44%

vs. S&P 500 +126.76% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in GALT

Vanguard Capital Management opened a new position in GALT, acquiring 1,966,542 shares valued at approximately $5.49 million. Marshall Wace increased its holdings by 617,778 shares, a 102.6% rise, bringing its total to 1,219,912 shares worth about $3.40 million. Osaic Holdings also boosted its stake by 32,080 shares, a 2.9% increase, ending with 1,122,670 shares valued at $3.13 million. BlackRock added 2,679 shares, a modest 0.3% increase, to hold a total of 799,237 shares valued at $2.23 million. Meanwhile, Millennium Management significantly expanded its position by 562,926 shares, a 239% jump, resulting in 798,434 shares worth $2.23 million.

Insider Buying and Selling at Galectin Therapeutics Inc.

On May 26, 2026, Jamil Khurram, Chief Medical Officer, executed both a sale and a purchase of 568 shares at $3.10 and $1.23 per share, respectively. Additionally, Brem Henry acquired 60,000 shares on March 12, 2026, while Eldred Kary bought 300 shares at $2.70 each on February 6, 2026.

Analysts Set New Price Targets

On June 23, 2026, HC Wainwright & Co. reiterated its buy rating on GALT with a price target of $11. This follows a December 17, 2025, rating where the firm maintained its buy stance with the same target. The consensus among analysts remains positive, with a buy recommendation and an average target price reflecting confidence in the stock's potential.

Bottom Line

HC Wainwright's reiterated buy rating and $11 target for GALT suggest continued optimism in the company's prospects. Institutional investors like Vanguard Capital Management and Millennium Management have shown interest, reflected in their recent stake increases. As always, remember that 13F filings and analyst ratings are backward-looking and may not represent current positions or outlooks.

12-month forecast